Compare BBN & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBN | EVO |
|---|---|---|
| Founded | 1983 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 964.6M | 1.1B |
| IPO Year | 2010 | N/A |
| Metric | BBN | EVO |
|---|---|---|
| Price | $16.03 | $3.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 208.3K | 47.1K |
| Earning Date | 01-01-0001 | 04-08-2026 |
| Dividend Yield | ★ 6.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | N/A | $10.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.47 | $2.31 |
| 52 Week High | $17.45 | $4.42 |
| Indicator | BBN | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 54.54 | 56.03 |
| Support Level | $15.53 | $2.88 |
| Resistance Level | $16.71 | $3.75 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 77.03 | 89.58 |
BlackRock Taxable Municipal Bond Trust is a diversified, closed-end management investment company. Its investment objective is to seek high current income, with a secondary objective of capital appreciation. The Trust seeks to achieve its investment objectives by investing in a portfolio of taxable municipal securities, including Build America Bonds (BABs), issued by state and local governments to finance capital projects such as public schools, roads, transportation infrastructure, bridges, ports and public buildings.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.